Article info

Download PDFPDF
Clinical trials
Effects of enzyme replacement therapy on the cardiomyopathy of Anderson–Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa
  1. Dr D A Hughes, Department of Academic Haematology, Royal Free and University College Medical School, Rowland Hill Street, London NW3 2PF, UK; d.hughes{at}medsch.ucl.ac.uk
View Full Text

Citation

Hughes DA, Elliott PM, Shah J, et al
Effects of enzyme replacement therapy on the cardiomyopathy of Anderson–Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa

Publication history

  • Accepted February 22, 2007
  • First published May 4, 2007.
Online issue publication 
October 25, 2017

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.